227 related articles for article (PubMed ID: 25548093)
1. Cancer immunotherapy achieves breakthrough status: 12th annual meeting of the association for cancer immunotherapy (CIMT), Mainz, Germany, May 6-8, 2014.
Kloke BP; Mahr A; Jabulowsky RA; Kutscher S; Rae R; Britten CM
Cancer Immunol Immunother; 2015 Jul; 64(7):923-30. PubMed ID: 25548093
[No Abstract] [Full Text] [Related]
2. CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Diken M; Boegel S; Grunwitz C; Kranz LM; Reuter K; van de Roemer N; Vascotto F; Vormehr M; Kreiter S
Hum Vaccin Immunother; 2014; 10(10):3090-100. PubMed ID: 25483671
[No Abstract] [Full Text] [Related]
3. Mechanisms of efficacy in cancer immunotherapy: 14th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 10-12, 2016.
Theelen J; Braun J; Hörzer H; Kloke BP; Ott M; Pizzitola I; Schirmer U; Miller M
Cancer Immunol Immunother; 2017 May; 66(5):673-681. PubMed ID: 28251274
[No Abstract] [Full Text] [Related]
4. CIMT 2013: advancing targeted therapies--report on the 11th Annual Meeting of the Association for Cancer Immunotherapy, May 14-16 2013, Mainz, Germany.
Diken M; Attig S; Grunwitz C; Kranz L; Simon P; van de Roemer N; Vascotto F; Kreiter S
Hum Vaccin Immunother; 2013 Sep; 9(9):2025-32. PubMed ID: 23877042
[TBL] [Abstract][Full Text] [Related]
5. CIMT 2017: Anniversary symposium - Report on the 15th CIMT Annual Meeting of the Association for Cancer Immunotherapy.
Kranz LM; Beck JD; Grunwitz C; Hotz C; Vormehr M; Diken M
Hum Vaccin Immunother; 2017 Oct; 13(10):2272-2279. PubMed ID: 28846471
[No Abstract] [Full Text] [Related]
6. Toward next-generation cancer immunotherapy: 10th annual meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 23-25, 2012.
Kloke BP; Kutscher S; Rae R; Kvistborg P; Britten CM; Hadrup SR
Cancer Immunol Immunother; 2013 May; 62(5):975-81. PubMed ID: 23299564
[No Abstract] [Full Text] [Related]
7. Toward the next waves of cancer immunotherapy: 11th Annual Meeting of the Association for Cancer Immunotherapy (CIMT), Mainz, Germany, May 14-16, 2013.
Kloke BP; Rae R; Mahr A; Burkhardt UE; Kvistborg P; Britten CM
Cancer Immunol Immunother; 2014 Jul; 63(7):749-55. PubMed ID: 24190545
[No Abstract] [Full Text] [Related]
8. Ninth annual meeting of the Association for Cancer Immunotherapy (CIMT 2011), May 25-27, 2011, Mainz, Germany.
Hobohm K; Seppmann T; Britten CM; Hoff H
Cancer Immunol Immunother; 2012 Jan; 61(1):137-43. PubMed ID: 22048716
[No Abstract] [Full Text] [Related]
9. Report on the sixth annual meeting of the Association for Immunotherapy of Cancer (CIMT), May 15 and 16, 2008 in Mainz, Germany.
Welters MJ; van Montfoort N; Khan S; Meyer RG; Britten CM
Cancer Immunol Immunother; 2009 May; 58(5):777-87. PubMed ID: 18982325
[No Abstract] [Full Text] [Related]
10. CIMT 2010: report on the eighth annual meeting of the Association for Cancer Immunotherapy, May 26-28, 2010, Mainz, Germany.
Singh SK; Laske K; Gouttefangeas C; Britten CM; Welters MJ
Cancer Immunol Immunother; 2011 Mar; 60(3):443-50. PubMed ID: 21104411
[No Abstract] [Full Text] [Related]
11. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
12. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
13. [New era of tumor immunotherapy].
Yoshitake Y; Nakatsura T; Nishimura Y
Nihon Rinsho; 2005 Apr; 63 Suppl 4():46-55. PubMed ID: 15861634
[No Abstract] [Full Text] [Related]
14. Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.
Antonarakis ES
Asian J Androl; 2012 Jul; 14(4):520-1. PubMed ID: 22580638
[No Abstract] [Full Text] [Related]
15. CIMT 2016: Mechanisms of efficacy in cancer immunotherapy - Report on the 14th Annual Meeting of the Association for Cancer Immunotherapy May 10-12 2016, Mainz, Germany.
Kranz LM; Birtel M; Hilscher L; Grunwitz C; Petschenka J; Vascotto F; Vormehr M; Voss RH; Kreiter S; Diken M
Hum Vaccin Immunother; 2016 Nov; 12(11):2805-2812. PubMed ID: 27435168
[No Abstract] [Full Text] [Related]
16. Combination immunotherapy approaches.
Drake CG
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii41-6. PubMed ID: 22918927
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy--revisited.
Lesterhuis WJ; Haanen JB; Punt CJ
Nat Rev Drug Discov; 2011 Aug; 10(8):591-600. PubMed ID: 21804596
[TBL] [Abstract][Full Text] [Related]
18. Adding fuel to the fire: immunogenic intensification.
O'Sullivan Coyne G; Gulley JL
Hum Vaccin Immunother; 2014; 10(11):3306-12. PubMed ID: 25483630
[TBL] [Abstract][Full Text] [Related]
19. CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer. June 3-5, Mainz, Germany.
Diken M; Widenmeyer M; Gouttefangeas C; Welters MJ; Britten CM
Cancer Immunol Immunother; 2010 Sep; 59(9):1417-23. PubMed ID: 19771427
[No Abstract] [Full Text] [Related]
20. Obstacles to T cell migration in the tumor microenvironment.
Nicolas-Boluda A; Donnadieu E
Comp Immunol Microbiol Infect Dis; 2019 Apr; 63():22-30. PubMed ID: 30961814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
